Physician profile
Phyllis Smith
NPI 1730307026
$1,555.96
in general payments reported to CMS, 2019-2025
12 companies · $25.85 in 2025
The $25.85 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $76.61 · 2021: $250 · 2022: $180 · 2023: $230 · 2024: $173 · 2025: $25.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.42 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $491.16 | 2019 | |
| Leo Pharma INC. | $321.00 | 2019-2023 | Adbry |
| Incyte Corporation | $157.30 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $150.55 | 2021-2025 | Absorica Ld, Winlevi |
| Abbvie INC. | $120.41 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $99.56 | 2024 | Zoryve |
| Janssen Biotech, INC. | $94.99 | 2023 | Tremfya |
| Almirall LLC | $38.93 | 2021-2022 | |
| Allergan, INC. | $38.34 | 2019-2020 | |
| Galderma Laboratories, L.P. | $17.20 | 2024 | Dysport |
| Genzyme Corporation | $13.47 | 2019 | |
| Pfizer INC. | $13.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.